Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 4 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar OKwarrior (45.95) Submitted: 6/9/2014 1:33:24 AM : Outperform Start Price: $35.54 ACOR Score: +7.00

biotech w/ actual cash flow and no negatives on the EPS. Valuations are pretty high, but that is because of the hope for the big score on MS drugs.

Featured Broker Partners


Advertisement